Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
103.22
-2.74 (-2.58%)
Dec 19, 2024, 12:39 PM EST - Market open
Novo Nordisk Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Novo Nordisk stock have an average target of 144.2, with a low estimate of 120 and a high estimate of 160. The average target predicts an increase of 39.70% from the current stock price of 103.22.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
The average analyst rating for Novo Nordisk stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | +55.00% | Nov 6, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $160 → $156 | Buy | Maintains | $160 → $156 | +51.13% | Oct 17, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | +55.00% | Oct 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | +55.00% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | +55.00% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
290.36B
from 232.26B
Increased by 25.02%
Revenue Next Year
349.79B
from 290.36B
Increased by 20.47%
EPS This Year
22.96
from 18.62
Increased by 23.28%
EPS Next Year
28.92
from 22.96
Increased by 25.98%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 305.9B | 381.3B | 466.9B | |||
| Avg | 290.4B | 349.8B | 411.6B | |||
| Low | 277.1B | 312.8B | 351.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 31.7% | 31.3% | 33.5% | |||
| Avg | 25.0% | 20.5% | 17.7% | |||
| Low | 19.3% | 7.7% | 0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 25.25 | 32.39 | 40.74 | |||
| Avg | 22.96 | 28.92 | 34.94 | |||
| Low | 21.45 | 25.22 | 29.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 35.6% | 41.1% | 40.9% | |||
| Avg | 23.3% | 26.0% | 20.8% | |||
| Low | 15.2% | 9.8% | 1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.